Type 1 Diabetes
New findings from Medical University of Graz describe advances in type 1 diabetes
Published in Obesity and Diabetes Week, June 16th, 2008
In this recent article published in the journal Diabetes Obesity & Metabolism, scientists in Graz, Austria conducted a study "To compare the end-organ metabolic effects of insulin glulisine (glulisine), insulin lispro (lispro) and regular human insulin (RHI) in patients with type 1 diabetes mellitus. Eighteen patients with type 1 diabetes mellitus (mean age 36.9 +/- 8.6 years, BMI 23.6 +/- 2.8 kg/m(2), haemoglobin A(1c) 7.4 +/- 0.9%) were randomized in this single-centre, double-blind, three-period cross-over, standard Latin-square, euglycaemic glucose clamp trial."
"Patients received sequential, primed stepwise intravenous infusions of glulisine, lispro or RHI...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Columbia University's Mailman School of Public Health
Children's consumption of sugar-sweetened beverages - University of Illinois at Urbana-Champaign
U of I study shows how to lose weight without losing bone - Cardioprotection
Scientists at University College publish new data on cardioprotection - Chirality
Study findings from P.C. Nair et al broaden understanding of chirality - Depression
University of Leuven reports research in depression - Diabetes
New diabetes findings from Toyama University published - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
